Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM DISODIUM VERSENATE vs DEPEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
Treatment of lead poisoning (including symptomatic and asymptomatic patients with blood lead levels ≥45 μg/d L in children and ≥70 μg/d L in adults),Off-label: treatment of other heavy metal toxicities (e.g., cadmium, chromium, manganese, nickel)
Wilson's disease,Cystinuria,Rheumatoid arthritis,Heavy metal poisoning (e.g., lead, mercury)
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Not metabolized; excreted unchanged in urine via glomerular filtration and tubular secretion.
Penicillamine is metabolized via oxidation to disulfides. It is primarily excreted in urine as unchanged drug and metabolites.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
<5% bound to plasma proteins (albumin)
80%; primarily to albumin.
0.2-0.3 L/kg; primarily distributes to extracellular fluid, minimal intracellular penetration
0.1-0.4 L/kg; indicates limited extravascular distribution, mainly confined to plasma and interstitial fluid.
IV: 100%; IM: approximately 80-90% (due to local chelation and partial excretion)
Oral: 40-70% (variable due to food and formulation).
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of usual dose; GFR < 10 m L/min: administer 25% of usual dose or consider alternative therapy.
GFR 30-59 m L/min: 250 mg every 8-12 hours; GFR 15-29 m L/min: 250 mg every 12-24 hours; GFR <15 m L/min: 250 mg every 24 hours or avoid use.
No specific guidelines available; use with caution and monitor liver function in severe hepatic impairment (Child-Pugh C).
No adjustment recommended for mild to moderate impairment (Child-Pugh A or B); avoid use in severe impairment (Child-Pugh C) due to increased risk of hepatotoxicity.
25 mg/kg/dose intramuscularly or intravenously every 12 hours for 3-5 days; maximum 1 g/dose.
Children >1 year: 10-15 mg/kg/day divided every 6-8 hours, maximum 500 mg/day.
Consider renal function; elderly patients often require dose reduction based on creatinine clearance; start at lower end of dosing range and monitor for adverse effects.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal function decline; monitor renal function and adjust based on creatinine clearance.
This drug is not indicated for the treatment of iron deficiency anemia or hemochromatosis. Do not use in patients with severe renal impairment. Prolonged or excessive use may lead to toxicities including renal failure, convulsions, and cardiac arrhythmias.
None.
Renal toxicity: monitor renal function and urine output; avoid excessive doses. Neurotoxicity: can cause tremors, seizures, and encephalopathy, especially with high doses or rapid infusion. Hydration: maintain adequate hydration to promote urinary excretion. Rebound metal mobilization: may transiently increase tissue metal levels. Hypocalcemia: due to calcium displacement; monitor serum calcium. Cardiac effects: risk of arrhythmias, especially with rapid IV administration.
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia),Proteinuria and nephrotic syndrome,Autoimmune reactions (lupus-like syndrome, myasthenia gravis),Hepatotoxicity,Severe skin reactions (e.g., pemphigus, Stevens-Johnson syndrome),Monitor renal function, blood counts, and urinalysis regularly
Absolute: anuria or severe renal failure (creatinine clearance <20 m L/min). Relative: hypersensitivity to edetate salts, pre-existing renal disease, concurrent use with other nephrotoxic drugs.
History of penicillamine-induced aplastic anemia or agranulocytosis,Pregnancy (relative contraindication due to teratogenicity),Renal insufficiency (avoid in severe impairment),Hypersensitivity to penicillamine
Avoid excessive intake of calcium and vitamin D supplements during therapy (may reduce chelation efficacy). Maintain adequate hydration with water. No specific food restrictions, but a balanced diet is recommended to prevent deficiencies of essential minerals (zinc, copper) that may be chelated.
Avoid foods high in copper (e.g., liver, shellfish, nuts, chocolate, mushrooms) during treatment for Wilson disease. For cystinuria, maintain high fluid intake (at least 3-4 liters/day) and reduce sodium and animal protein to decrease cystine excretion. Vitamin B6 supplementation may be needed as DEPEN can increase pyridoxine requirements.
Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fetal zinc/corper deficiency if prolonged use. Avoid unless maternal benefit outweighs risk.
Penicillamine (Depen) is associated with severe fetal malformations including cutis laxa and skeletal abnormalities when used during pregnancy. First trimester exposure carries highest risk; use is contraindicated unless necessary for maternal conditions like Wilson's disease or cystinuria. Second and third trimester use may cause fetal connective tissue disorders.
Excreted into breast milk in low amounts; M/P ratio unknown. Caution due to potential for infant mineral chelation. Use only if clearly needed.
Penicillamine is excreted into breast milk in low amounts; M/P ratio not well defined. Potential for infant toxicity (e.g., rash, bone marrow suppression). Caution advised; monitor infant for adverse effects. Alternative therapies preferred.
No specific dose adjustment required; however, monitor for hypocalcemia and mineral depletion. Increased risk of renal toxicity in pregnancy; ensure adequate hydration.
No standard dose adjustment defined; use lowest effective dose. Pharmacokinetics not well studied; increased clearance may require dose titration. Monitor clinical response and copper levels in Wilson's disease.
Administer deep IM or slow IV infusion (over 2-4 hours) to avoid thrombophlebitis. Monitor urine output and renal function; nephrotoxicity is dose-dependent. Discontinue if oliguria or rising creatinine occurs. For lead encephalopathy, give concurrently with BAL (dimercaprol) to redistribute lead from CNS to blood. Use with caution in patients with pre-existing renal disease, hepatitis, or history of allergic reactions. EDTA can chelate essential metals (zinc, copper) leading to deficiencies during prolonged therapy.
DEPEN (penicillamine) is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for proteinuria and hematuria due to immune complex nephropathy. Cross-sensitivity with penicillin possible. Administer on empty stomach for Wilson disease; with meals for cystinuria to reduce GI upset. Avoid concomitant use with other nephrotoxic drugs.
Report any signs of allergic reaction (rash, itching, difficulty breathing) or injection site pain/swelling immediately.,Drink plenty of fluids (unless instructed otherwise) to help flush out lead through urine.,Avoid taking any other medications, supplements, or over-the-counter products without consulting your doctor, as they may affect treatment.,Do not miss scheduled blood and urine tests; they are essential to monitor lead levels and kidney function.,Severe lead poisoning may cause fatigue, headache, abdominal pain; report these symptoms if they worsen.
Take DEPEN on an empty stomach at least 1 hour before or 2 hours after meals, unless otherwise directed for cystinuria.,Do not skip doses; consistent intake is critical for Wilson disease to prevent copper accumulation.,Report any signs of infection, unusual bleeding, skin rash, or changes in urine color or output immediately.,Avoid alcohol completely as it may increase risk of liver toxicity.,Use effective contraception during therapy as DEPEN can cause fetal harm.,Have regular blood and urine tests as ordered to monitor for side effects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM DISODIUM VERSENATE vs DEPEN, answered by our medical review team.
CALCIUM DISODIUM VERSENATE is a Chelating Agent that works by Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.. DEPEN is a Chelating Agent that works by Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM DISODIUM VERSENATE and DEPEN depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM DISODIUM VERSENATE is: 1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.. The standard adult dose of DEPEN is: 250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM DISODIUM VERSENATE and DEPEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM DISODIUM VERSENATE is classified as Category C. Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fet. DEPEN is classified as Category C. Penicillamine (Depen) is associated with severe fetal malformations including cutis laxa and skeletal abnormalities when used during pregnancy. First trimester exposure carries hig. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.